Steven Cohen Replimune Group, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $7.65 Million - $12.7 Million	-437,900 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $6.29 Million - $10.3 Million	368,075 Added 527.14%	437,900 $11.9 Million
Q3 2022 Nov 14, 2022	SELL	$15.6 - $21.15 $1.84 Million - $2.5 Million	-117,975 Reduced 62.82%	69,825 $1.21 Million
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $8.88 Million - $13.3 Million	-667,000 Reduced 78.03%	187,800 $3.28 Million
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $7.84 Million - $15.3 Million	514,600 Added 151.26%	854,800 $14.5 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $8.65 Million - $11.7 Million	340,200 New	340,200 $9.22 Million
Q3 2021 Nov 15, 2021	SELL	$28.98 - $39.54 $4.67 Million - $6.38 Million	-161,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$28.5 - $39.37 $12.9 Million - $17.9 Million	-453,978 Reduced 73.78%	161,300 $6.2 Million
Q1 2021 May 17, 2021	SELL	$30.22 - $45.57 $5.13 Million - $7.74 Million	-169,822 Reduced 21.63%	615,278 $18.8 Million
Q4 2020 Feb 16, 2021	SELL	$23.5 - $52.65 $4.74 Million - $10.6 Million	-201,816 Reduced 20.45%	785,100 $30 Million
Q3 2020 Nov 16, 2020	BUY	$18.85 - $27.0 $18.6 Million - $26.6 Million	986,916 New	986,916 $22.7 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $694M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.